<DOC>
	<DOC>NCT00189748</DOC>
	<brief_summary>To assess safety and efficacy of the patients with MR4 therapy in GVHD prophylaxis study who are eligible for the administration after 100 days post transplant (up to 1 year)</brief_summary>
	<brief_title>A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation (MR4) in BMT Patients-Extension-</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patient had enrolled in GVHD prophylaxis study. Patient had been fully informed. The patient had been not eligible for the administration after 100 days post transplant in the investigator's judgement.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Bone Marrow Transplantation</keyword>
	<keyword>Graft versus Host Disease</keyword>
</DOC>